Immunohistochemical neuroendocrine differentiation is an independent prognostic factor in surgically resected large cell carcinoma of the lung

被引:27
作者
Harada, M
Yokose, T
Yoshida, J
Nishiwaki, Y
Nagai, K
机构
[1] Natl Canc Ctr, Res Inst E, Div Pathol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr, Res Inst E, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan
关键词
large cell carcinoma; neuroendocrine differentiation; large cell neuroendocrine carcinoma; LCNEC; surgical intervention;
D O I
10.1016/S0169-5002(02)00181-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The clinical significance of neuroendocrine (NE) differentiation is unclear in large cell carcinoma (LCC) of the lung. Fifty-five surgically resected carcinomas of the lung with an original pathologic diagnosis of LCC were reviewed histologically with special attention to NE morphology. Antibodies against neural cell adhesion molecule (NCAM), chromogranin A (CGA) and synaptophysin (SY) were used to confirm the NE differentiation. Thirteen (24%) cases were classified as large cell neuroendocrine carcinoma, 9 (16%) as LCC with NE differentiation, and 33 (60%) as pure LCC. There was no significant difference in overall survival between the three groups. When the 55 carcinomas were divided into three groups depending on the number of NE marker expression, there was significantly better overall survival in the NE greater than or equal to 2 (P = 0.02). Multivariate analysis proved NE greater than or equal to 2 was an independent predictor of survival. The number of NE markers was more important in terms of survival than histological subclassification. Crown Copyright (C) 2002 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 26 条
  • [1] [Anonymous], HIST TYPING LUNG PLE
  • [2] ARRIGONI MG, 1972, J THORAC CARDIOV SUR, V64, P413
  • [3] CLINICAL CHARACTERIZATION OF NON-SMALL-CELL LUNG-CANCER TUMORS SHOWING NEURO-ENDOCRINE DIFFERENTIATION FEATURES
    BERENDSEN, HH
    DELEIJ, L
    POPPEMA, S
    POSTMUS, PE
    BOES, A
    SLUITER, HJ
    THE, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1614 - 1620
  • [4] NEUROENDOCRINE DIFFERENTIATION AS A PROGNOSTIC FACTOR IN NONSMALL CELL LUNG-CANCER
    CARLES, J
    ROSELL, R
    ARIZA, A
    PELLICER, I
    SANCHEZ, JJ
    FERNANDEZVASALO, G
    ABAD, A
    BARNADAS, A
    [J]. LUNG CANCER, 1993, 10 (3-4) : 209 - 219
  • [5] DRANOFF G, 1984, ARCH PATHOL LAB MED, V108, P535
  • [6] GOULD VE, 1983, PATHOL ANNU, V18, P287
  • [7] GRAZIANO SL, 1994, CANCER RES, V54, P2908
  • [8] THE USE OF NEURO-ENDOCRINE IMMUNOPEROXIDASE MARKERS TO PREDICT CHEMOTHERAPY RESPONSE IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER
    GRAZIANO, SL
    MAZID, R
    NEWMAN, N
    TATUM, A
    OLER, A
    MORTIMER, JA
    GULLO, JJ
    DIFINO, SM
    SCALZO, AJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) : 1398 - 1406
  • [9] HAIMOTO H, 1985, LAB INVEST, V52, P257
  • [10] USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES
    HSU, SM
    RAINE, L
    FANGER, H
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) : 577 - 580